AMGN - Amgen Inc.
| Previous Close | 177.96 |
| Open | 177.96 |
| Bid | 178.00 x 800 |
| Ask | 178.24 x 900 |
| Day's Range | 177.64 - 179.08 |
| 52 Week Range | 153.56 - 201.23 |
| Volume | 1,550,346 |
| Avg. Volume | 4,740,693 |
| Market Cap | 118.708B |
| Beta | 1.70 |
| PE Ratio (TTM) | 66.26 |
| EPS (TTM) | 2.69 |
| Earnings Date | Jul 23, 2018 - Jul 27, 2018 |
| Forward Dividend & Yield | 5.28 (2.99%) |
| Ex-Dividend Date | 2018-05-16 |
| 1y Target Est | 195.35 |
Market Realist•11 hours agoTeva’s Fremanezumab Gets September Action Date from FDA
On May 23, 2018, Teva (TEVA) announced that the FDA’s Prescription Drug User Fee Act action date is set for September 16, 2018, for its migraine drug Fremanezumab. Also, the company stated that there are no additional data requirements from the FDA, and it’s likely to launch the drug by mid-September. According to Brendan O’Grady, head of Teva’s North America Commercial division, “We are preparing to launch the product immediately when approved.
Market Realist•12 hours agoBarclays Raises Its 12-Month Target Price on Teva Stock
On May 24, 2018, Barclays (BCS) increased its 12-month target price on Teva Pharmaceutical Industries (TEVA) from $13 to $20. The increased target price represents a potential investment return of ~15.7% over the next 12 months. On May 24, Teva stock closed trading with a rise of 2.3% as compared to the stock’s closing price on the previous day.
- Market Realist•17 hours ago
A Brief Overview of Merck’s First-Quarter Performance
Merck & Company (MRK) reported revenue of $10.0 billion in Q1 2018 compared to $9.4 billion in Q1 2017, which reflected a ~6% rise YoY (year-over-year) and a ~4% fall sequentially. In Q1 2018, Merck saw a ~2% positive impact from foreign exchange.
- Market Realist•21 hours ago
Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
How Is Alnylam Pharmaceuticals Positioned in 2018? Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21. Overall, Alnylam Pharmaceuticals has fallen 24%.
- American City Business Journals•yesterday
Why this Peninsula startup is primed for an $80.5 million IPO
Kezar Life Sciences Inc., which would trade on the NASDAQ exchange as "KZR," is the fifth Bay Area life sciences company this year to file for an IPO, and it's indicative of the ability founders have to go public early on in the process of building a drug development company. Spun out of Amgen Inc. with small molecules from the plate of the former Onyx Pharmaceuticals Inc., the South San Francisco company is developing drugs for autoimmune diseases, where the immune system starts attacking healthy cells. Its first drug, KZR-616, is enrolling patients in a mid-stage Phase Ib/II study in lupus and lupus nephritis, or inflammation in the kidney.
- Market Realist•yesterday
What Drove Ionis’s Revenue in Q1
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.
- Market Realist•yesterday
Ionis Pharmaceuticals’ Valuation on May 23
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.
- Market Realist•2 days ago
Analyst Views on the Upside Potential of Alnylam Pharmaceuticals
How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals (ALNY) is a global biopharmaceutical company focused on developing RNA interference-based novel therapeutics. Alnylam is harnessing this pathway to develop a new class of innovative medicines called RNAi therapeutics.
- ETF Trends•2 days ago
Will “Right to Try” Bill Boost Biotech ETFs?
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, and other biotechnology assets traded slightly higher Wednesday after the U.S. House of Representatives on Tuesday passed “right to try” legislation. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.
- InvestorPlace•2 days ago
3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More
A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.
- Motley Fool•2 days ago
Is This Little Biotech the Best Migraine Stock to Buy Now?
The big dogs have a head start, but this small-cap biotech could have a lot more to gain.
- PR Newswire•3 days ago
Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment
THOUSAND OAKS, Calif., May 23, 2018 /PRNewswire/ -- Amgen (AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Center and the University of California, San Diego (UCSD) Design Lab to support the improvement of cancer outcomes. The L.A.U.N.C.H. (Linking & Amplifying User-Centered Networks through Connected Health) program will use human-centered design methodologies to identify the needs of patients, caregivers and healthcare providers.
- Zacks•3 days ago
Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.
- Forbes•3 days ago
New Drug Costs Are Still High, But Putting Prices In TV Ads Offers Little Value
Last week, the Trump administration, via secretary of health and human services, Alex Azar, proposed that drug makers be required to include the list prices of drugs in all direct-to-consumer ads. In addition, payers are providing support for the prices being set. Just last week, Amgen announced that the price of its new migraine drug, Aimovig, would be set at $6,900 per year.
- PR Newswire•3 days ago
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
THOUSAND OAKS, Calif., May 22, 2018 /PRNewswire/ -- Amgen (AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 90 percent of outstanding shares were represented at the meeting. The director nominees Wanda M. Austin, Robert A. Bradway, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Frank C. Herringer, Charles M. Holley, Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors.
- Investor's Business Daily•3 days ago
Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene
Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.
Market Realist•4 days agoRoche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.
- Zacks•4 days ago
Amgen's Label Expansion Application for Prolia Gets FDA Nod
Amgen (AMGN) announces FDA approval for its regulatory application seeking label expansion for Prolia.
- Benzinga•4 days ago
Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 21) AstraZeneca plc (ADR) (NYSE: AZN ) (FDA approved its ...
- The Wall Street Journal•4 days ago
New Migraine Drugs Offer Hope to Sufferers
Lisa DeLeonardo set a Google alert so she would know exactly when the first in a new class of migraine drugs was approved. It happened Thursday, when the U.S. Food and Drug Administration approved Amgen and Novartis’ application for erenumab, whose brand name is Aimovig. It’s an injectable drug touted as the first treatment designed specifically to prevent migraines, and is expected to be available to patients within a week for an annual price of $6,900.
- American City Business Journals•4 days ago
Regional cycling fans show up in numbers for Amgen Tour (PHOTOS)
Northern California showed itself to be an accommodating and receptive host for the 13th annual Amgen Tour of California.
- PR Newswire•5 days ago
FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. This approval is based on data from a Phase 3 study which showed patients on glucocorticoid therapy who received Prolia had greater gains in bone mineral density (BMD) compared to those who received active comparator (risedronate).
- Zacks•5 days ago
Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod
Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.
- TheStreet.com•7 days ago
CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI
After a heated week of litigation battles, CBS on Thursday proceeded with a board meeting it had scheduled to vote on whether to dilute the voting power of National Amusements Inc., a company controlled by Shari Redstone. This came after a court decision that said CBS could not prevent Redstone from changing CBS's bylaws to prevent that from occurring. All of which means CBS directors and Redstone will be back in court soon to fight over voting control, with Redstone pushing to combine CBS with Viacom, unless of course, both sides instead consider the option to auction the media company.
